Apoptosis imaging probe predicts early chemotherapy response in preclinical models: A comparative study with 18F-FDG PET

Journal of Nuclear Medicine

Volumn 54, Issue 1, 2013, Pages 104-110

  Song, Shaoli ^a,b   Xiong, Chiyi ^b   Lu, Wei ^b,c   Ku, Geng ^b   Huang, Gang ^a   Li, Chun ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

18F FDG; Apoptosis imaging; Chemotherapy; PET; SAAC(99mTc) PSBP 6

Indexed keywords

CYCLOPHOSPHAMIDE; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; TECHNETIUM SINGLE AMINO ACID CHELAE PHOSPHATIDYLSERINE BINDING PEPTIDE CONJUGATE TC 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MELANOMA; MOLECULAR IMAGING; MOUSE; NICK END LABELING; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTISCANNING; SINGLE DRUG DOSE; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; FEMALE; FLUORODEOXYGLUCOSE F18; LYMPHOMA; MELANOMA, EXPERIMENTAL; MICE; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84872028876     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.109397     Document Type: Article

References (34)

1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
2. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693.
3. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698.
4. Weissleder R. Molecular imaging in cancer. Science. 2006;312:1168-1171.
5. Bleeker-Rovers CP, Vos FJ, van der Graaf WT, Oyen WJ. Nuclear medicine imaging of infection in cancer patients (with emphasis on FDG-PET). Oncologist. 2011;16:980-991.
6. 18F-FDG PET and PET/CT in the evaluation of cancer treatment response. J Nucl Med. 2009;50:88-99.
7. 18F- fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009;115:5038-5047.
8. Shah C, Miller TW, Wyatt SK, et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res. 2009;15:4712-4721.
9. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267:1456-1462.
10. Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol. 2003;79:927-941.
11. Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer. 1994;73:2013-2026.
12. Schimmer AD, Welsh K, Pinilla C, et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell. 2004;5:25-35.
13. Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 1998;58:4453-4460.
14. De Saint-Hubert M, Bauwens M, Verbruggen A, Mottaghy FM. Apoptosis imaging to monitor cancer therapy: the road to fast treatment evaluation? Curr Pharm Biotechnol. 2012;13:571-583.
15. Blankenberg FG, Katsikis PD, Tait JF, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA. 1998;95:6349-6354.
16. 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med. 2005;46:658-666.
17. 99mTc-annexin V. J Nucl Med. 2005;46:807-815.
18. Zhang R, Lu W, Wen X, et al. Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med. 2011;52:958-964.
19. 99mTc-labeled C2A in the area at risk after myocardial ischemia and reperfusion. J Nucl Med. 2007;48:1031-1036.
20. 99mTc C2A, a domain of synaptotagmin I: a preliminary study. Nucl Med Biol. 2008;35:359-364.
21. Chen DL, Zhou D, Chu W, et al. Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. Nucl Med Biol. 2009;36:651-658.
22. 18F]fluoroethylazide. J Med Chem. 2008;51:8057-8067.
23. Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, Ziv I. Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med. 2010;51:837-840.
24. Lahorte CM, Vanderheyden JL, Steinmetz N, Van de Wiele C, Dierckx RA, Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging. 2004;31:887-919.
25. Xiong C, Brewer K, Song S, et al. Peptide-based imaging agents targeting phosphatidylserine for the detection of apoptosis. J Med Chem. 2011;54:1825-1835.
26. Li C, Yu DF, Newman RA, et al. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. Cancer Res. 1998;58:2404-2409.
27. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 2002;4:235-242.
28. Schmitt CA, Lowe SW. Apoptosis is critical for drug response in vivo. Drug Resist Updat. 2001;4:132-134.
29. Tolomeo M, Simoni D. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Curr Med Chem Anticancer Agents. 2002;2:387-401.
30. Swairjo MA, Seaton BA. Annexin structure and membrane interactions: a molecular perspective. Annu Rev Biophys Biomol Struct. 1994;23:193-213.
31. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol. 2005;6:449-461.
32. Skaane P. Molecular imaging: a potential new tool for early detection and monitoring of targeted breast cancer therapy. Acta Radiol. 2009;50:1092-1093.
33. Kenis H, Hofstra L, Reutelingsperger CP. Annexin A5: shifting from a diagnostic towards a therapeutic realm. Cell Mol Life Sci. 2007;64:2859-2862.
34. 18F-FDG, and histologic evaluation. J Nucl Med. 2005;46:794-799.